Replies to post #213937 on Biotech Values

[DewDiligence]

DXCM—Some comments on the magnitude of the hit from ABT’s Freestyle Libre:

http://www.barrons.com/articles/dexcom-stay-sweet-or-go-sour-1506610819

What’s curious about DXCM’s recent price action is that FDA approval of ABT’s device was not unexpected.